Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N8Q1

UPID:
C56D1_HUMAN

ALTERNATIVE NAMES:
Cytochrome b561 domain-containing protein 1

ALTERNATIVE UPACC:
Q8N8Q1; B4DH97; E9PCM8; Q52M36; Q5T6C2; Q5T6C3

BACKGROUND:
CYB561D1, with its alternative name Cytochrome b561 domain-containing protein 1, is identified as a probable transmembrane reductase. This protein is pivotal in electron transport, leveraging ascorbate to reduce various cellular components, including monodehydro-L-ascorbate radical and iron cations Fe(3+), thereby maintaining cellular redox homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of CYB561D1 offers a promising pathway to novel therapeutic interventions. Its critical role in maintaining redox balance within cells underscores its potential in developing strategies for disease management and prevention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.